Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell Short Hobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunotherapy against anti PD 1 monotherapy. The discussion focuses on why toxicity rises without clear efficacy gains, and what these results mean for adjuvant and neoadjuvant strategy going forward. James Larkin and Sapna Patel also dig into a bigger question: if combination therapy helps in metastatic disease, why does it seem to lose its edge in microscopic or...
这一集暂时还没有文字稿
你仍然可以在播放器中收听。有文字稿的节目,点任意单词就能看到释义。
